A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results